Ramona Heddergott-Schulz

Goettingen, NI, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer.

TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer.

Journal: Science advances

Published: July 04, 2025

Targeting macrophage migration inhibitory factor as a potential therapeutic strategy in colorectal cancer.

Targeting macrophage migration inhibitory factor as a potential therapeutic strategy in colorectal cancer.

Journal: Oncogenesis

Published: March 11, 2025

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Journal: Cell death and differentiation

Published: September 04, 2024

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Journal: bioRxiv : the preprint server for biology

Published: March 11, 2024

Real-Time Metabolic Magnetic Resonance Spectroscopy of Pancreatic and Colon Cancer Tumor-Xenografts with Parahydrogen Hyperpolarized 1-13C Pyruvate-d3.

Real-Time Metabolic Magnetic Resonance Spectroscopy of Pancreatic and Colon Cancer Tumor-Xenografts with Parahydrogen Hyperpolarized 1-13C Pyruvate-d3.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: January 16, 2024

CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan.

CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan.

Journal: Cell cycle (Georgetown, Tex.)

Published: June 02, 2023

The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53.

The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53.

Journal: Blood

Published: June 01, 2022

Preparation and Cultivation of Colonic and Small Intestinal Murine Organoids Including Analysis of Gene Expression and Organoid Viability.

Preparation and Cultivation of Colonic and Small Intestinal Murine Organoids Including Analysis of Gene Expression and Organoid Viability.

Journal: Bio-protocol

Published: July 12, 2021

The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.

The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.

Journal: Frontiers in oncology

Published: December 16, 2020

Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer.

Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer.

Journal: Cell death & disease

Published: December 11, 2020

Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity.

Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity.

Journal: Nature communications

Published: February 11, 2020

Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Journal: Cell death and differentiation

Published: September 05, 2018

Showing 1-12 of 17

Last Updated: 09/26/2026